MedTrace Logo

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

NCT04273516 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-10-19

No results posted yet for this study

Summary

Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year.

Despite recent scientific advances in acute ischemic stroke treatment in recent decades,consensus treatment of all guidelines is still ASA

Conditions

Interventions

DRUG

Rivaroxaban 2.5 Mg Oral Tablet

Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily

DRUG

Rivaroxaban placebo tablets

Placebo tablets add to ASA 80 mg daily that is standard treatment

Sponsors & Collaborators

  • Mazandaran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Athena Sharifi-Razvi · mazandaran university of medical science

  • Monireh Ghazaeian · mazandaran university of medical science

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-22
Primary Completion
2023-04-10
Completion
2023-04-30
FDA Drug
Yes

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04273516 on ClinicalTrials.gov